(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
0.77% £ 18.39
Live Chart Being Loaded With Signals
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...
Stats | |
---|---|
Dzisiejszy wolumen | 254 775 |
Średni wolumen | 546 210 |
Kapitalizacja rynkowa | 17.53M |
EPS | £0 ( 2024-04-10 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.07 |
ATR14 | £0.232 (1.26%) |
Destiny Pharma PLC Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
WINE.L | 0.9 |
GHT.L | 0.889 |
INDV.L | 0.883 |
DPEU.L | 0.873 |
ONC.L | 0.859 |
MCM.L | 0.853 |
RMMC.L | 0.842 |
UPGS.L | 0.834 |
RWS.L | 0.833 |
DGN.L | 0.829 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Destiny Pharma PLC Finanse
Annual | 2023 |
Przychody: | £831 552 |
Zysk brutto: | £831 552 (100.00 %) |
EPS: | £-0.0624 |
FY | 2023 |
Przychody: | £831 552 |
Zysk brutto: | £831 552 (100.00 %) |
EPS: | £-0.0624 |
FY | 2022 |
Przychody: | £154 499 |
Zysk brutto: | £142 171 (92.02 %) |
EPS: | £-0.0926 |
FY | 2021 |
Przychody: | £0.00 |
Zysk brutto: | £0.00 (0.00 %) |
EPS: | £-0.0890 |
Financial Reports:
No articles found.
Destiny Pharma PLC
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej